Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;84(5):e80-e81.
doi: 10.1016/j.jinf.2022.02.005. Epub 2022 Feb 12.

Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concern

Pragya D Yadav  1 , Gajanan N Sapkal  2 , Rima R Sahay  2 , Varsha A Potdar  2 , Gururaj R Deshpande  2 , Deepak Y Patil  2 , Dimpal A Nyayanit  2 , Anita M Shete  2 , Jayanthi Shastri  3 , Pradip Awate  4 , Bharti Malhotra  5 , Priya Abraham  2
Affiliations

Substantial immune response in Omicron infected breakthrough and unvaccinated individuals against SARS-CoV-2 variants of concern

Pragya D Yadav et al. J Infect. 2022 May.
No abstract available

Keywords: Breakthrough; IgG antibodies; Neutralization; Omicron; SARS-CoV-2; Vaccination.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Authors do not have a conflict of interest among themselves.

Figures

Fig. 1
Fig. 1
IgG antibody response in breakthrough and unvaccinated individuals was assessed using ELISA (A) S1-RBD (B) N protein (C) Inactivated whole antigen. The IgG antibody titers of the different groups were compared using the two-tailed Kruskal Wallis test and the p-value less than 0.05 were considered to be statistically significant. The neutralizing antibody response among (D) ChAdOx1 nCoV-19 breakthrough (E) BNT162b2 mRNA breakthrough and (F) unvaccinated individuals against B.1, Alpha, Beta, Delta and Omicron were determined using the plaque reduction neutralization test (PRNT50). The titers amongst the groups were compared with B.1 using the Wilcoxon matched-pairs signed-rank test to assess the statistical significance.
See this image and copyright information in PMC

References

    1. Dimeglio C., Migueres M., Mansuy J.M., Saivin S., Miedougé M., Chapuy-Regaud S., et al. Antibody titers and breakthrough infections with Omicron SARS-CoV-2. J Infect. 2022 doi: 10.1016/j.jinf.2022.01.044. , S0163-4453–3. doi: - DOI - PMC - PubMed
    1. World Health Organization. Enhancing response to Omicron SARS-CoV-2 variant: Technical brief and priority actions for Member States. https://www.who.int/docs/default-source/coronaviruse/2022-01-07-global-t.... Accessed 18 January 2022.
    1. Wolter N., Jassat W., Walaza S., Welch R., Moultrie H., Groome M., et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399(10323):437–446. doi: 10.1016/S0140-6736(22)00017-4. - DOI - PMC - PubMed
    1. Ella R., Reddy S., Jogdand H., Sarangi V., Ganneru B., Prasad S., et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021;21(7):950–961. doi: 10.1016/S1473-3099(21)00070-0. - DOI - PMC - PubMed
    1. Deshpande G.R., Sapkal G.N., Tilekar B.N., Yadav P.D., Gurav Y., Gaikwad S., et al. Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients. Indian J Med Res. 2020;152(1–2):82. - PMC - PubMed

Publication types

Substances

Supplementary concepts